Biohit Oyj - Company Announcement

Biohit Oyj’s new B-shares have been registered with the Trade Register as a part of the share exchange agreement with Genetic Analysis AS

Biohit Oyj Stock Exchange Release February 12, 2016 at 09:30 local time (EET)

As a part of the share exchange agreement announced on January 5, 2016 Biohit
Oyj has executed a directed share issue of 350,000 pcs Biohit Oyj’s new class B
shares to Genetic Analysis AS. 

The new class B shares have been registered with the Trade Register on February
12, 2016, and the shares carry with them the same shareholder rights as the
outstanding class B shares as of the date of the registration. The trading in
the new shares is expected to commence as of February 15, 2016 on NASDAQ OMX
Helsinki together with the outstanding B shares. 

The share subscription price is paid with a contribution in-kind corresponding
to 8,543,036 pcs Genetic Analysis AS shares and 18 % of all Genetic Analysis AS
shares. Biohit Oyj’s share capital remains unchanged as the shares have no
nominal value. 

Following the subscription the total number of Biohit Oyj shares will increase
to 14,698,533 shares (14,348,533) and the total number of class B shares to
11,723,033 shares (11,373,033). The new shares correspond to 2.38 % of total
outstanding shares and 0.49 % share of voting rights after the registration. 

The directed share issue is based on the 14th of December 2015 Board
resolution, based on the 14th of April 2014 Annual General Meeting
authorisation. 



Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit Oyj Stock Exchange Release January 22, 2016: Genetic Analysis AS general
meeting has approved the share exchange with Biohit Oyj 

Biohit Oyj Stock Exchange Release January 5, 2016: Biohit Oyj buys a share of
Norwegian Genetic Analysis AS –company with a directed share issue 


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com 


Genetic Analysis AS in brief

Genetic Analysis has developed and launched the first bacterial gene-based
clinical test for the mapping and diagnosis of diseases related to dysbiosis
and imbalances in the digestive system. The company markets the GA-map™
technology to three market segments: commercial routine clinical testing,
pharma companies and the research market. Genetic Analysis was established in
2008 and is based on research done by Professor Knut Rudi and Nofima Mat in Ås,
Norway. www.genetic-analysis.com/